title: [Cladribine monotherapy for patients with relapsed or refractory indolent non-Hodgkin lymphoma].
abstract: Cladribine is a purine analogue that is resistant to degradation by adenosine deaminase. We describe the efficacy of cladribine monotherapy in 8 patients with relapsed or refractory indolent non-Hodgkin lymphoma. The median age of the patients was 57 years. All patients were given 1-3 courses of cladribine monotherapy at 0.09 mg/kg/day continuous infusion for 7 days. Although all patients had been treated with rituximab and CHOP-like regimens, the response rate was excellent (85.7%). Thus we consider that cladribine is the first treatment of choice in the patients with relapsed or refractory indolent lymphoma.
authors.affiliation: Department of Hematology, National Hospital Organization Kyushu Cancer Center.
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Nakashima
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Shimada
authors.forename: Yu
authors.initials: Y
authors.lastname: Yamada
authors.forename: Ilseung
authors.initials: I
authors.lastname: Choi
authors.forename: Yuji
authors.initials: Y
authors.lastname: Yufu
authors.forename: Naokuni
authors.initials: N
authors.lastname: Uike
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D017338:Cladribine / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D017338:Cladribine